Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Phase II Randomized Trial Combining TG01 Vaccine / QS-21 Stimulon With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer TESLA
Study Type: Treatment
Phase: II
NCTID: NCT05638698
Principal Investigator:
Anup Kasi
A Phase Ib/II trial of Onvansertib in Combination with NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
Study Type: Treatment
Phase: I/II
NCTID: NCT06736717
Principal Investigator:
Anup Kasi
GRECO-2: A Randomized, Phase II Study of Stereotactic Body Radiation Therapy SBRT in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer
A Phase I/II Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 in Combination with Gemcitabine in Subjects with Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed on Prior Treatment with 5-Fluorouacil-based Chemotherapy
Study Type: Treatment
Phase: I/II
NCTID: NCT03854110
Principal Investigator:
Anup Kasi
A Phase 2 Study of Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Study Type: Treatment
Phase: II
NCTID: NCT04752696
Principal Investigator:
Anup Kasi
A Phase Ib/IIa Trial Of CEND?1 In Combination With Neoadjuvant FOLFIRINOX Based Therapies In Pancreatic, Colon And Appendiceal Cancers CENDIFOX
Study Type: Treatment
Phase: I/II
NCTID: NCT05121038
Principal Investigator:
Anup Kasi
A Phase III, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer
Study Type: Treatment
Phase: III
NCTID: NCT03941093
Principal Investigator:
Anup Kasi
Pancreatic Cancer Early Detection PRECEDE Consortium
A Phase II Study of 9-ING-41 GSK-3? Combined with Retifanlimab plus Gemcitabine/Nab-Paclitaxel as Frontline Therapy for Patients with Advanced Pancreatic Adenocarcinoma
A Phase 1/2 Study of M3814 Peposertib in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Study Type: Treatment
Phase: I/II
NCTID: NCT04172532
Principal Investigator:
Anup Kasi